A detailed history of Rhumbline Advisers transactions in Ardelyx, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 320,054 shares of ARDX stock, worth $1.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
320,054
Previous 337,967 5.3%
Holding current value
$1.54 Million
Previous $2.5 Million 11.94%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$5.28 - $7.57 $94,580 - $135,601
-17,913 Reduced 5.3%
320,054 $2.21 Million
Q2 2024

Aug 01, 2024

BUY
$5.89 - $9.31 $2,314 - $3,658
393 Added 0.12%
337,967 $2.5 Million
Q1 2024

May 09, 2024

BUY
$6.05 - $9.74 $65,400 - $105,289
10,810 Added 3.31%
337,574 $2.46 Million
Q4 2023

Feb 08, 2024

BUY
$3.29 - $6.64 $73,432 - $148,204
22,320 Added 7.33%
326,764 $2.03 Million
Q3 2023

Nov 09, 2023

BUY
$3.3 - $4.83 $30,191 - $44,189
9,149 Added 3.1%
304,444 $1.24 Million
Q2 2023

Aug 08, 2023

BUY
$3.23 - $4.95 $953,802 - $1.46 Million
295,295 New
295,295 $1 Million
Q2 2022

Aug 11, 2022

SELL
$0.51 - $1.17 $49,970 - $114,637
-97,981 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$0.65 - $1.18 $1,830 - $3,322
2,816 Added 2.96%
97,981 $105,000
Q4 2021

Feb 10, 2022

SELL
$0.86 - $1.7 $2,064 - $4,080
-2,400 Reduced 2.46%
95,165 $105,000
Q3 2021

Nov 12, 2021

BUY
$1.27 - $8.17 $4,305 - $27,696
3,390 Added 3.6%
97,565 $129,000
Q2 2021

Aug 05, 2021

BUY
$6.55 - $8.98 $59,146 - $81,089
9,030 Added 10.61%
94,175 $714,000
Q1 2021

May 06, 2021

SELL
$6.1 - $7.69 $63,927 - $80,591
-10,480 Reduced 10.96%
85,145 $564,000
Q4 2020

Feb 10, 2021

BUY
$5.05 - $7.1 $53,227 - $74,834
10,540 Added 12.39%
95,625 $619,000
Q3 2020

Nov 12, 2020

SELL
$5.25 - $7.08 $70,166 - $94,624
-13,365 Reduced 13.58%
85,085 $447,000
Q2 2020

Aug 13, 2020

BUY
$5.37 - $8.11 $8,876 - $13,405
1,653 Added 1.71%
98,450 $681,000
Q1 2020

May 06, 2020

BUY
$4.35 - $8.79 $98,201 - $198,434
22,575 Added 30.42%
96,797 $550,000
Q4 2019

Feb 05, 2020

BUY
$4.23 - $8.29 $4,158 - $8,149
983 Added 1.34%
74,222 $557,000
Q3 2019

Oct 23, 2019

BUY
$2.15 - $6.28 $12,947 - $37,818
6,022 Added 8.96%
73,239 $344,000
Q2 2019

Aug 14, 2019

BUY
$2.49 - $3.73 $16,536 - $24,770
6,641 Added 10.96%
67,217 $181,000
Q1 2019

May 01, 2019

BUY
$1.88 - $3.35 $1,981 - $3,530
1,054 Added 1.77%
60,576 $170,000
Q4 2018

Jan 31, 2019

BUY
$1.66 - $4.16 $37,658 - $94,373
22,686 Added 61.59%
59,522 $107,000
Q3 2018

Nov 07, 2018

BUY
$3.75 - $4.65 $14,100 - $17,484
3,760 Added 11.37%
36,836 $160,000
Q2 2018

Aug 06, 2018

BUY
$3.7 - $5.8 $1,091 - $1,711
295 Added 0.9%
33,076 $122,000
Q1 2018

May 02, 2018

SELL
$5.05 - $7.9 $9,595 - $15,010
-1,900 Reduced 5.48%
32,781 $166,000
Q4 2017

Feb 09, 2018

SELL
$4.85 - $7.8 $31,888 - $51,285
-6,575 Reduced 15.94%
34,681 $229,000
Q3 2017

Nov 06, 2017

BUY
$4.35 - $5.7 $179,463 - $235,159
41,256
41,256 $231,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $742M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.